Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Opal-HIV-Gag
- Development stage
- Unknown
- Lead developer
- Medicines Development for Global Health
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Opal-HIV-Gag is an autologous cell-based therapeutic vaccine developed by Medicines Development for Global Health for the treatment of HIV infection. The Overlapping Peptide-pulsed Autologous Cells (Opal) technology involves the ex vivo pulsing of a patient's own peripheral blood mononuclear cells (PBMCs) or whole blood with a library of overlapping peptides derived from the HIV-1 Gag protein (specifically Clade C). These sensitized cells are then re-infused into the patient to prime and expand HIV-specific CD4+ and CD8+ T-cell responses. This immunotherapy aims to enhance the host's ability to control viral replication, potentially reducing the reliance on lifelong antiretroviral therapy.
- Other names
- Overlapping Peptide-pulsed Autologous Cells HIV-Gag
02
Targets
Gag (HIV-1 Gag polyprotein)MHC I (MHC class I})HIV-1 Gag-specific T-cell receptor (HIV-1 Gag-specific TCR)MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on Opal-HIV-Gag.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Opal-HIV-Gag.